Article
169 Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through three years: long-term data from the FUTURE 1 and FUTURE 2 studies
Rheumatology
(2018)
Disciplines
Publication Date
April 1, 2018
DOI
10.1093/rheumatology/key075.393
Citation Information
Hector Chinoy, Laure Gossec, Tore K Kvien, Philip G Conaghan, et al.. "169 Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through three years: long-term data from the FUTURE 1 and FUTURE 2 studies" Rheumatology Vol. 57 (2018) Available at: http://works.bepress.com/philip-mease/10/